Scarica l'app Stockscreener
6.24
10.44%
0.59
Dopo l'orario di chiusura:
6.22
-0.02
-0.32%
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit - PR Newswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - globenewswire.com
ARS Pharmaceuticals (NASDAQ: SPRY) CCO files first insider report with no shares - Stock Titan
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.6% HigherHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact Levi & Korsinsky - globenewswire.com
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmace - The National Law Review
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
2026-08-16 | SPRY DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ARS Pharmaceuticals Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:SPRY | Press Release - Stockhouse
ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen - Sahm
Analysts Have Lowered Expectations For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Its Latest Results - simplywall.st
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuti - The National Law Review
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit - timothysykes.com
Cantor Fitzgerald Remains a Buy on ARS Pharmaceuticals (SPRY) - The Globe and Mail
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
(SPRY) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings - MarketBeat
Attention Long-Term Shareholders of ARS Pharmaceuticals, - globenewswire.com
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals earnings missed by $0.13, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ - The National Law Review
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action DeadlineContact the Firm Before October 5, 2026 - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results - Investing News Network
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report - Investing.com
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings - Quiver Quantitative
ARS Pharma Q2 Results: Revenue up 114% YoY, net loss widens - scanx.trade
ARS Pharmaceuticals (Nasdaq: SPRY) doubles Q2 2026 revenue but posts larger loss - Stock Titan
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY - TMX Newsfile
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) - TMX Newsfile
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ARS Pharmaceuticals, Inc. ... - Caledonian Record
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings - Yahoo Finance
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earni - GuruFocus
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Sahm
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - Barchart.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals Investors Face October Lawsuit Deadline - stl.news
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - ycharts.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - globenewswire.com
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Eyeing a 352% Potential Upside in Biotechnology - DirectorsTalk Interviews
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASD - The National Law Review
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit ... - Caledonian Record
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - globenewswire.com
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals - globenewswire.com
SPRY Class Action ReminderRobbins LLP Reminds Investors - globenewswire.com
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, - GlobeNewswire
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc. - Morningstar
SPRY Deadline Alert: The Gross Law Firm Reminds ARS - GlobeNewswire
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):